Press Release
2022-03-10
NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new preclinical data for the company’s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Association for Cancer Research (AACR) annual meeting, to be held in New Orleans on April 8-13, 2022. The data come from two studies evaluating NT-I7, a novel long-acting human IL-7, 1. in combination with hIL-2/TCB2c complex, and 2. in combination with anti-TIGIT or anti-VEGF therapies.
Details related to the poster presentations are as follows:
Title: rhIL-7-hyFc (efineptakin alfa; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex
Lead Author: Seungtae Baek, Research Institute of NeoImmuneTech
Abstract Number: 4199
Poster Session: Combination Immunotherapies 2
Title: rhIL-7-hyFc (efineptakin alfa; NT-I7) enhances the anti-tumor response when combined with anti TIGIT or anti-VEGF
Lead Author: Seungtae Baek, Research Institute of NeoImmuneTech
Abstract Number: 4172
Poster Session: Combination Immunotherapies 1